377 related articles for article (PubMed ID: 30664790)
21. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
Parra K; Valenzuela P; Lerma N; Gallegos A; Reza LC; Rodriguez G; Emmenegger U; Di Desidero T; Bocci G; Felder MS; Manciu M; Kirken RA; Francia G
Br J Cancer; 2017 Jan; 116(3):324-334. PubMed ID: 28056464
[TBL] [Abstract][Full Text] [Related]
22. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
Latimer P; Menchaca M; Snyder RM; Yu W; Gilbert BE; Sanders BG; Kline K
Exp Biol Med (Maywood); 2009 Oct; 234(10):1244-52. PubMed ID: 19657067
[TBL] [Abstract][Full Text] [Related]
23. Delineating the anti-metastatic potential of pentoxifylline in combination with liposomal doxorubicin against breast cancer cells.
Goel PN; Gude RP
Biomed Pharmacother; 2014 Mar; 68(2):191-200. PubMed ID: 24373697
[TBL] [Abstract][Full Text] [Related]
24. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
25. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
Hoffmann O; Aktas B; Goldnau C; Heubner M; Oberhoff C; Kimmig R; Kasimir-Bauer S
Anticancer Res; 2011 Oct; 31(10):3623-8. PubMed ID: 21965788
[TBL] [Abstract][Full Text] [Related]
26. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
Xiang J; Hurchla MA; Fontana F; Su X; Amend SR; Esser AK; Douglas GJ; Mudalagiriyappa C; Luker KE; Pluard T; Ademuyiwa FO; Romagnoli B; Tuffin G; Chevalier E; Luker GD; Bauer M; Zimmermann J; Aft RL; Dembowsky K; Weilbaecher KN
Mol Cancer Ther; 2015 Nov; 14(11):2473-85. PubMed ID: 26269605
[TBL] [Abstract][Full Text] [Related]
27. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
[TBL] [Abstract][Full Text] [Related]
28. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
[TBL] [Abstract][Full Text] [Related]
29. Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.
Lan Q; Peyvandi S; Duffey N; Huang YT; Barras D; Held W; Richard F; Delorenzi M; Sotiriou C; Desmedt C; Lorusso G; Rüegg C
Oncogene; 2019 Apr; 38(15):2814-2829. PubMed ID: 30546090
[TBL] [Abstract][Full Text] [Related]
30. The perivascular niche regulates breast tumour dormancy.
Ghajar CM; Peinado H; Mori H; Matei IR; Evason KJ; Brazier H; Almeida D; Koller A; Hajjar KA; Stainier DY; Chen EI; Lyden D; Bissell MJ
Nat Cell Biol; 2013 Jul; 15(7):807-17. PubMed ID: 23728425
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
Herbst RS; Takeuchi H; Teicher BA
Cancer Chemother Pharmacol; 1998; 41(6):497-504. PubMed ID: 9554595
[TBL] [Abstract][Full Text] [Related]
32. Unfavorable effect of calcitriol and its low-calcemic analogs on metastasis of 4T1 mouse mammary gland cancer.
Anisiewicz A; Pawlik A; Filip-Psurska B; Turlej E; Dzimira S; Milczarek M; Gdesz K; Papiernik D; Jarosz J; Kłopotowska D; Kutner A; Mazur A; Wietrzyk J
Int J Oncol; 2018 Jan; 52(1):103-126. PubMed ID: 29115583
[TBL] [Abstract][Full Text] [Related]
33. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
34. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.
Zeng Q; Yang Z; Gao YJ; Yuan H; Cui K; Shi Y; Wang H; Huang X; Wong ST; Wang Y; Kesari S; Ji RR; Xu X
Eur J Cancer; 2010 Apr; 46(6):1132-43. PubMed ID: 20156674
[TBL] [Abstract][Full Text] [Related]
35. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Papadopoulou MV; Ji M; Bloomer WD
Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of EpCAM-positive disseminated tumor cells in rectal cancer patients with stage I disease.
Dhayat S; Sorescu S; Vallböhmer D; Kraus S; Baldus SE; Rehders A; Kröpil F; Krieg A; Knoefel WT; Stoecklein NH
Am J Surg Pathol; 2012 Dec; 36(12):1809-16. PubMed ID: 23060348
[TBL] [Abstract][Full Text] [Related]
37. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
38. Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients.
Cabinakova M; Mikulova V; Malickova K; Vrana D; Pavlista D; Petruzelka L; Zima T; Tesarova P
Neoplasma; 2015; 62(2):259-68. PubMed ID: 25591591
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
Ottewell PD; Brown HK; Jones M; Rogers TL; Cross SS; Brown NJ; Coleman RE; Holen I
Breast Cancer Res Treat; 2012 Jun; 133(2):523-36. PubMed ID: 21956211
[TBL] [Abstract][Full Text] [Related]
40. PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice.
Chen Y; Wang L; Liu H; Song F; Xu C; Zhang K; Chen Q; Wu S; Zhu Y; Dong Y; Zhou M; Zhang H; Tian M
Mol Imaging Biol; 2018 Apr; 20(2):309-317. PubMed ID: 28795272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
